SlidesetHIVEarly treatment and clinical outcomes – does early ART make a difference?- Louise Kuhn, PhDView Slideset
SlidesetHIVControllers: post-treatment vs elite controllers – what do we know?- Phillip Goulder, MA, FRCPCH, DPhil, FMedScView Slideset
SlidesetHIVHIV vaccines and broadly neutralizing monoclonal antibody - role in the cure agenda- Sandhya Vasan, MDView Slideset
SlidesetHIVDebate: All children should be switched to dolutegravir-based ART regimens CON- Nandita SugandhiView Slideset
SlidesetHIVDebate: All children should be switched to dolutegravir-based ART regimens PRO- Adeodata Kekitiinwa, MBChB, MMedView Slideset
SlidesetHIVMobile technology for engaging children and youth in treatment and prevention- Lisa Hightow-Weidman MD, MPHView Slideset
SlidesetHIVToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants- Mark Mirochnick MDView Slideset
SlidesetHIVChallenges and successes in implementing rapid infant diagnostic testing- Patricia Fassinou, MDView Slideset
SlidesetHIVUpdates on PMTCT from Malawi, the country where Option B+ started- Maria Kim, MDView Slideset
SlidesetHIVAntiretroviral treatment for pregnant and breastfeeding women: current status of implementation and EMTCT- Shaffiq Essajee, MDView Slideset
SlidesetHIVDebate: All infants should receive oral antiretroviral prophylaxis throughout breastfeeding: CON- Amy Slogrove, MB ChB, MMed, PhDView Slideset
SlidesetHIVDebate: All infants should receive oral antiretroviral prophylaxis throughout breastfeeding: PRO- Philippe van der Perre, MD, PhDView Slideset
SlidesetHIVThe emerging pediatric population: youth with behaviorally-acquired HIV- Sarah Bernays, PhDView Slideset
